|Rexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol to FDA|
|By Staff and Wire Reports|
|Wednesday, 03 March 2010 09:09|
“The progression of Zoraxel’s clinical program is very encouraging,” said Rexahn Chief Executive Officer, Dr. Chang Ahn. “We believe that the future of ED treatment lies in compounds that act on the central nervous system and effectively modify the condition, rather than targeting end organ erectile function. Zoraxel has the potential to be the first drug capable of this action and to establish a new standard of care for erectile dysfunction.”
The Phase IIb study will continue to assess Zoraxel’s efficacy in approximately 225 male subjects, ages 18 to 65, with ED. The double blind, randomized, placebo-controlled, 12-week study will include the Sexual Encounter Profile (SEP) survey, International Index of Erectile Function (IIEF) and quality of life study endpoints and will be conducted at multiple sites in the U.S. Data from the Phase IIa study completed in May 2009 reported that subjects treated with Zoraxel demonstrated improved erectile function and significant improvement in the quality of life measures. The study also found Zoraxel to be safe and well tolerated, with no serious adverse events reported.
Rexahn also announced the formation of a Urology Scientific Advisory Board (
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.